Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals
Article Abstract:
Giving HIV patients 1,000 milligrams (mg) of saquinavir in combination with 100 mg of ritonavir leads to greater blood levels of saquinavir than the traditional doses of 400 mg each. In addition, the lower dose of ritonavir caused fewer side effects.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir
Article Abstract:
A study was conducted to quantify the change in saquinavir (SQV) and amprenavir (APV) exposure when combined and used with low-dose ritonavir and to evaluate safety and immunologic and virologic response. Further, the results revealed that protease inhibitor (PI) dosage adjustments were based on real-time pharmacokinetics assessment and that saquinavir did not affect amprenavir or ritonavir pharmacokinetics.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Penetration of 3'-amido-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients
Article Abstract:
A potentially dangerous by-product of zidovudine (ZDV) called 3'-amino-3'-deoxythymidine (AMT) appears to be present in the spinal fluid of patients with HIV-1 treated with ZDV. AMT and ZDV levels were measured in spinal fluid and some plasma samples of 23 patients with HIV-1 treated with ZDV. AMT and ZDV levels were equivalent in both plasma and spinal fluid samples with a median concentration of 1.7 nanograms per milliliter. Patients with toxoplasmosis in the brain, however, had equivalent AMT and ZDV levels that were three times higher than uninfected patients.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Marked variation in responses to long-term nitric oxide inhibition during pregnancy in outbred rats from two different colonies
- Abstracts: A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir
- Abstracts: Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population
- Abstracts: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS clinical trials group 5108 study
- Abstracts: Effect of menstruation and intrapelvic injection of endometrium on inflammatory parameters of peritoneal fluid in the baboon (Papio anubis and Papio cynocephalus)